Brittany Lovely

Managing Editor, OncLive®
Brittany Lovely is a managing editor for the OncologyLive® print publication and editor of the Miami Breast Cancer Conference® and Chemotherapy Foundation Symposium® dailies. Email: blovely@mjhassoc.com

Articles

Investigators Seek to Expand Treatment Options for aGVHD with Novel Anti-CD6 Agent

March 29th 2022

Corey S. Cutler, MD, MPH, FRCPC, notes the clinical benefit observed with itolizumab in EQUATE and the observations that informed the design of the phase 3 EQUATOR trial.

E-Selectin Presents a Favorable Path Forward for AML Populations

March 28th 2022

In acute myeloid leukemia, investigators are exploring novel agents engineered to target adhesion factors, which can mobilize persistent leukemic stem cells from the bone marrow niche.

Investigators Look Beyond Immune Checkpoint Inhibitors to Chase Moving Targets in Prostate Cancer

March 16th 2022

Immune checkpoint inhibitors represent only one area of effective therapy for patients with advanced prostate cancer, but they are not “be all, end all” of immunotherapy options.

HER2 Expression Drives Treatment Decisions in Gastric/Esophageal Cancers

March 14th 2022

Experts in the field of upper gastrointestinal cancers discuss recent data from the European Society for Medical Oncology Congress 2021 that may bolster the uptake of HER2 as a guide for treatment decisions in the second line.

Folding CAR T-cell Therapy Into Relapsed/Refractory MCL Treatment

March 9th 2022

Treatment with the CD19-directed CAR T-cell therapy brexucabtagene autoleucel demonstrated significant activity, marked by high response rates and prolonged survival, in patients with relapsed mantle cell lymphoma in the pivotal ZUMA-2 trial.

Alleviating the Burden of Financial Toxicity Begins at the Point of Care

March 8th 2022

Safety profiles of anticancer drugs represent only one piece of the toxicity puzzle patients grapple with following a cancer diagnosis.

Ultra-Rare Sarcoma Subgroup Sees First Treatment Option

March 7th 2022

Nab-sirolimus became a treatment option for a rare, aggressive soft-tissue sarcoma—malignant perivascular epithelioid cell tumor—following encouraging data in the first prospective clinical trial for this patient population.

Risk-Adaptive Approaches Offer Safer, Effective Strategies for Early-Stage HER2+ Breast Cancer

March 5th 2022

The integration of HER2-targeted therapies into the treatment paradigm for patients with early-stage breast cancer, specifically the standard trastuzumab, has shifted focus away from whether patients should receive to how and when they should receive treatment with these agents.

Investigators Push to Leverage Liquid Biopsy As New Standard in Early Detection, Prognosis of Hematologic Malignancies

March 3rd 2022

Leveraging the advances made with liquid biopsies in pantumor assays and specific hematologic cancers has laid the groundwork for the shift in care by using single, or multifaceted approaches for identifying, predicting, and monitoring disease progression.

Efforts to Target NRG1 Unlock New Pathways for Treatment

March 1st 2022

Early data have demonstrated poor outcomes for patients with NRG1 fusions, and limited efficacy with available treatments represents a need for the development of novel therapeutic agents.

Investigators Tackle the Untapped Potential of Personalized Medicine

February 26th 2022

Improving patient outcomes is top of mind for investigators at John Theurer Cancer Center in Hackensack, New Jersey.

Relapsed/Refractory Follicular Lymphoma Has a Bounty of Options in the Third Line

February 24th 2022

Caron A. Jacobson, MD, MMSc, and a panel of experts, talk about the evolving landscape for patients with relapsed or refractory follicular lymphoma, plus data on PI3K inhibitors and CAR T-cell therapies.

Key Data Illuminate New Directions in HER2-Positive Metastatic Breast Cancer Landscape

February 23rd 2022

An abundance of riches in the form of new data for HER2-targeted agents continues to drive progress for patients with metastatic breast cancer.

First-in-Class AR Agonist Opens Doors for ER-Positive Metastatic Breast Cancer

February 17th 2022

Androgen recepter positivity serves as an independent predictor of beneficial outcomes in breast cancer.

Treatment Strategies for Relapsed/Refractory MCL Represent a Unique Challenge

February 8th 2022

Despite the breakthroughs in the development of therapeutic regimens for patients with mantle cell lymphoma, variability in treatment pathways presents a unique hurdle in determining the appropriate course of care following disease progression.

Modest Budget Effects Demonstrate Promise for Uptake of Genomic Profiling in NSCLC

January 27th 2022

The identification of actionable oncogenetic drivers in patients with non–small cell lung cancer affords clinicians the opportunity to use targeted agents to optimize outcomes.

Novel Oncolytic Immunotherapy Aims to Address Unmet Therapeutic Need for Anti–PD-1 Refractory Tumors

January 19th 2022

Investigators have taken strides to genetically engineer novel oncolytic immunotherapies that synergize with existing immunotherapies to maximize antitumor response in anti–PD-1 refractory tumors.

Targeting CD166 Represents a New Avenue of Attack for Breast Cancer

January 12th 2022

High expression of activated leukocyte cell adhesion molecule, also known as CD166, occurs in approximately 50% of patients with triple-negative breast cancer and up to 80% of patients with estrogen receptor– positive, HER2-negative breast cancer.

Novel Combination Looks to Capitalize on Synergy of B7-H3/PD-1 Blockade

December 30th 2021

The investigational monoclonal antibody enoblituzumab has demonstrated activity in preclinical studies and in combination with pembrolizumab in phase 1/2 studies in patients with checkpoint inhibitor–naïve head and neck squamous cell carcinoma and non–small cell lung cancer.

Full-Dose Pacritinib Bests Ruxolitinib for Patients With Cytopenic Myelofibrosis

December 14th 2021

Most patients with myelofibrosis with moderate to severe thrombocytopenia treated with pacritinib were able to maintain full dose intensity over time and had numerically higher rates of symptom response vs those who received ruxolitinib.